Lilly's Weight Loss Pill Falls Short of Novo's Wegovy in Key Study
Published on: Aug. 7, 2025, 7:04 p.m. | Source: Devdiscourse
Eli Lilly's GLP-1 pill, orforglipron, led to 12.4% weight loss in a 72-week study, falling short of Novo Nordisk's Wegovy. Despite the results, Lilly plans to seek global approval, highlighting the pill's potential for convenience and its heart health benefits.
